Smith & Nephew plc (LON:SN) Stock Has Average Price Target of GBX 1,293.33

Smith & Nephew plc (LON:SN) has been given a consensus recommendation of “Hold” by the nine brokerages that are currently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is GBX 1,293.33.

SN has been the subject of a number of recent research reports. Jefferies Financial Group reiterated a “buy” rating and set a GBX 1,500 price target on shares of Smith & Nephew in a report on Friday, September 4th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 1,250 price objective on shares of Smith & Nephew in a research report on Tuesday, September 15th. Shore Capital Group reissued a “buy” rating and set a GBX 1,000 price objective on shares of Smith & Nephew in a research note on Tuesday, July 21st. Citigroup lowered shares of Smith & Nephew to a “buy” rating in a research report on Friday, July 10th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating on the stock in a research report on Thursday, August 6th.

Smith & Nephew Trading Up 1.1%

Shares of SN stock opened at GBX 1,049 on Friday. The firm has a market cap of £11.50 billion, a P/E ratio of 37.77, a price-to-earnings-growth ratio of 0.46 and a beta of 0.69. The company has a quick ratio of 0.84, a current ratio of 2.14 and a debt-to-equity ratio of 73.07. The company has a fifty day moving average price of GBX 1,051.07 and a 200-day moving average price of GBX 1,117.74.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.